Atypical Mycobacteriosis Treatment Global Market Report 2025

The atypical mycobacteriosis treatment market size has grown strongly in recent years. It will grow from $2.26 billion in 2024 to $2.4 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. Growth during the historic period can be attributed to the rising prevalence of HIV, improved diagnostic techniques, increased awareness of mycobacterial infections, greater use of immunosuppressive therapies, and the expansion of infectious disease research.

The atypical mycobacteriosis treatment market size is expected to see strong growth in the next few years. It will grow to $3.02 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. Growth in the forecast period is expected to be driven by the aging population, rising demand for macrolide antibiotics, greater focus on treatments for orphan diseases, expanded healthcare access, and more clinical trials for nontuberculous mycobacterial infections. Key trends in the forecast period include advancements in rapid molecular diagnostics, the development of targeted drug therapies, the integration of telemedicine for infection management, increased investment in antimicrobial resistance research, and the use of artificial intelligence in treatment planning.

The increasing prevalence of infections is expected to drive the growth of the atypical mycobacteriosis treatment market in the coming years. Infections occur when microorganisms such as bacteria, viruses, or fungi invade and multiply in the body, leading to symptoms or disease. The rise in infections is primarily due to increasing antimicrobial resistance, which diminishes the effectiveness of standard treatments and allows pathogens to spread more easily. Atypical mycobacteriosis treatment addresses these infections by targeting and eliminating non-tuberculous mycobacterial pathogens, reducing inflammation, and preventing further disease progression. For example, in November 2023, the Centers for Disease Control and Prevention (CDC) reported that the United States recorded 8,331 tuberculosis cases in 2022, marking a 5.9% increase from 2021. Therefore, the rising prevalence of infections is a key factor driving the growth of the atypical mycobacteriosis treatment market.

The growing demand for personalized therapies is also expected to contribute to market growth. Personalized therapies refer to medical treatments that are tailored to an individual's unique genetic, biological, and environmental factors, optimizing treatment effectiveness. The demand for such therapies is mainly driven by advancements in genomics and biotechnology, which enable the development of treatments customized to an individual’s genetic profile, improving efficacy and reducing side effects. Atypical mycobacteriosis treatment plays a crucial role in personalized therapies, as it allows for tailored treatment strategies based on a patient’s specific genetic and clinical characteristics. For instance, in February 2024, the Personalized Medicine Coalition reported that in 2023, the FDA approved 16 new personalized treatments for rare diseases, a significant increase from just six approved in 2022. As such, the growing demand for personalized therapies is helping to fuel the growth of the atypical mycobacteriosis treatment market.

The rising incidence of chronic obstructive pulmonary disease (COPD) is also expected to drive the market forward. COPD refers to a group of progressive lung diseases, including emphysema and chronic bronchitis, that cause airflow obstruction and breathing problems. The increase in COPD cases is largely attributed to tobacco smoke, as prolonged exposure to harmful chemicals in tobacco damages the lungs and airways, leading to chronic inflammation and reduced airflow. Atypical mycobacteriosis treatment aids COPD management by reducing the bacterial load and inflammation caused by non-tuberculous mycobacteria, which can worsen respiratory symptoms and accelerate disease progression. For instance, in June 2024, the Australian Institute of Health and Welfare reported that COPD accounted for 3.6% of Australia’s total disease burden in 2023, representing 50% of the total burden from respiratory conditions, up from 2.5% in 2022, reflecting a 44% increase in disease burden. Therefore, the rising incidence of COPD is driving the growth of the atypical mycobacteriosis treatment market.

Major players in the atypical mycobacteriosis treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Zydus Pharmaceuticals, Lupin Limited, Gland Pharma Limited, Saphnix Lifesciences Pvt. Ltd., Gentec Pharmaceutical Group, and Octavius Pharma Pvt. Ltd.

North America was the largest region in the atypical mycobacteriosis treatment market in 2024. The regions covered in atypical mycobacteriosis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the atypical mycobacteriosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Atypical mycobacteriosis treatment involves managing infections caused by nontuberculous mycobacteria (NTM), which are a group of mycobacterial species that do not lead to tuberculosis. These infections can affect areas such as the lungs, skin, and lymph nodes, and are often more resistant to standard tuberculosis therapies. Treatment generally requires a combination of antibiotics, including macrolides, rifamycins, and ethambutol, usually over an extended period.

The primary treatment options for atypical mycobacteriosis include antibiotic therapy, surgical interventions, combination therapy, and supportive care. Antibiotic therapy typically consists of long-term use of targeted antibiotics such as macrolides, aminoglycosides, and fluoroquinolones to eliminate or control the growth of atypical mycobacteria and prevent relapse. This approach is applied to various infections, including lung infections, disseminated infections, and skin or soft tissue infections, with administration via oral, intravenous, or topical routes. Treatment is provided to diverse patient groups, including immunocompromised individuals, non-immunocompromised patients, and children, and is delivered by different healthcare providers, such as hospitals, clinics, and home care settings.

The atypical mycobacteriosis treatment market research report is one of a series of new reports that provides atypical mycobacteriosis treatment market statistics, including atypical mycobacteriosis treatment industry global market size, regional shares, competitors with a atypical mycobacteriosis treatment market share, atypical mycobacteriosis treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the atypical mycobacteriosis treatment industry. This atypical mycobacteriosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The atypical mycobacteriosis treatment market consists of revenues earned by entities by providing services such as diagnosis and screening, consultation and care management, surgical intervention, patient education and support services, telemedicine services, inpatient and outpatient care, personalized treatment plans, pharmacovigilance and drug monitoring, nutritional support and counseling, and laboratory and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The atypical mycobacteriosis treatment market also includes sales of clarithromycin, azithromycin, rifampin, ethambutol, amikacin, streptomycin, rifabutin, pyrazinamide, interferons, probiotics, pulmonary inhalers, mucolytics, chronic infection management treatments, and diagnostic tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.